ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ビルダグリプチン

Vildagliptin

HCID 6918537
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
274901-16-5
標準SMILES
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2
InChIKey
SYOKIDBDQMKNDQ-XWTIBIIYSA-N
分子式
C17H25N3O2
平均分子量
303.4 g/mol

概要

Vildagliptin is an amino acid amide.

名称と識別子

優先名称
Vildagliptin
IUPAC
(2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile
現地名
ビルダグリプチン
英語名
Vildagliptin
分子式
C17H25N3O2
分子量
303.4

名称と別名

VildagliptinGalvus274901-16-5NVP-LAF237EquaLAF237LAF-237VitagliptinNVP-LAF 237(2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrilevildagliptineVildagliptina
名称をさらに表示
ビルダグリプチンビルダグリプチン (JAN)ビルダクリプチン(2S)-1-[[(3-ヒドロキシトリシクロ[3.3.1.13,7]デカン-1-イル)アミノ]アセチル]-2-ピロリジンカルボニトリル(2S)-1-(2-{[(5R,7S)-3-ヒドロキシアダマンタン-1-イル]アミノ}アセチル)ピロリジン-2-カルボニトリル(2S)-1-{[(3-ヒドロキシトリシクロ[3.3.1.13,7]デカン-1-イル)アミノ]アセチル}ピロリジン-2-カルボニトリル(2S)-1-[[(3-ヒドロキシトリシクロ[3.3.1.13,7]デカン-1-イル)アミノ]アセチル]ピロリジン-2-カルボニトリルエクアVigliptinVildgliptinVildagliptin (LAF-237)ZOMELIS1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine(2S)-1-(2-((3-hydroxyadaMantan-1-yl)aMino)acetyl)pyrrolidine-2-carbonitrile(-)-(2S)-1-[[(3-Hydroxytricyclo[3.3.1.1[3,7]]dec-1-yl)amino]acetyl]pyrrolidine-2-carbonitriledagLLaf 237
I6B4B2U96P(2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrileDTXSID80881091vildagliptinumNVP LAF237(2S)-1-(2-((3-hydroxy-1-adamantyl)amino)acetyl)pyrrolidine-2-carbonitrileRefChem:6349(2S)-{((3-Hydroxyadamantan-1-yl)amino)acetyl}pyrrolidine-2-carbonitrile

データベース識別子

CAS
274901-16-5
PubChem CID
6918537
ChEMBL
CHEMBL142703
ChEBI
CHEBI:135285
UNII
I6B4B2U96P
EC Number
630-410-0

物性

構造計算による物性

XLogP
0.9
極性表面積
76.4 Ų
水素結合供与体数
2
水素結合受容体数
4
回転可能結合数
3
重原子数
22
形式電荷
0
複雑度
523

実験および物理化学的性質

DrugsPharmaceuticals -> Used in Switzerland
Solubility1.75e+00 g/L
Human Drugs · 3 件

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

Physical DescriptionSolid

物理化学的性質

融点
153 · 153-155C
比旋光度
-78.3 ° · -78.3° (c = 9.73 in methanol)
沸点
531.3 · 531.3±50.0 °C(Predicted)
比重(密度)
1.27 · 1.27
闪点
275.1 ℃ · 275.1℃
貯蔵温度
-20 °C · Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
溶解性
DMSO (最大 45mg/ml)、DMF (最大 20mg/ml) またはエタノール (最大 20mg/ml) に可溶。
酸解離定数(Pka)
15.05 · 15.05±0.40(Predicted)
外見
個体
色
白い
安定性
2 · 購入日から2年間安定です。 DMSO、DMF、またはエタノールに溶解したこの溶液は、-20°C で 3 か月間保存できます。

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

This chemical does not meet GHS hazard criteria for 1.4% (1 of 71) of reports.

H413 (90.1%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard]

P273, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 71 reports by companies from 10 notifications to the ECHA C&L Inventory.

危険有害性情報

Hazard Classes and CategoriesAquatic Chronic 4 (90.1%)

安全データ

wgk
WGK 3
ridadr
3077
hs_code
29339900
risk_code
28-38-41-48
safety_code
24/25-26-28-36/37/39
ストレージクラス
11 - Combustible Solids

化学と産業

薬理情報

ATC Code · 3 件

A10BH02

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein BindingThe plasma protein binding of vildagliptin is 9.3%. Vildagliptin distributes equally between plasma and red blood cells.
Pharmacodynamics · 1 件

Vildagliptin works to improve glycemic control in type II diabetes mellitus by enhancing the glucose sensitivity of beta-cells (β-cells) in pancreatic islets and promoting glucose-dependent insulin secretion. Increased GLP-1 levels leads to enhanced sensitivity of alpha cells to glucose, promoting glucagon secretion. Vildagliptin causes an increase in the insulin to glucagon ratio by increasing incretin hormone levels: this results in a decrease in fasting and postprandial hepatic glucose production. Vildagliptin does not affect gastric emptying. It also has no effects on insulin secretion or blood glucose levels in individuals with normal glycemic control. In clinical trials, treatment with vildagliptin 50-100 mg daily in patients with type 2 diabetes significantly improved markers of beta-cells, proinsulin to insulin ratio, and measures of beta-cell responsiveness from the frequently-sampled meal tolerance test. Vildagliptin has improves glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) levels.

Mechanism of Action · 1 件

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are incretin hormones that regulate blood glucose levels and maintain glucose homeostasis. It is estimated that the activity of GLP-1 and GIP contribute more than 70% to the insulin response to an oral glucose challenge. They stimulate insulin secretion in a glucose-dependent manner via G-protein-coupled GIP and GLP-1 receptor signalling. In addition to their effects on insulin secretion, GLP-1 is also involved in promoting islet neogenesis and differentiation, as well as attenuating pancreatic beta-cell apoptosis. Incretin hormones also exert extra-pancreatic effects, such as lipogenesis and myocardial function. In type II diabetes mellitus, GLP-1 secretion is impaired, and the insulinotropic effect of GIP is significantly diminished. Vildagliptin exerts its blood glucose-lowering effects by selectively inhibiting dipeptidyl peptidase-4 (DPP-4), an enzyme that rapidly truncates and inactivates GLP-1 and GIP upon their release from the intestinal cells. DPP-4 cleaves oligopeptides after the second amino acid from the N-terminal end. Inhibition of DPP-4 substantially prolongs the half-life of GLP-1 and GIP, increasing the levels of active circulating incretin hormones. The duration of DPP-4 inhibition by vildagliptin is dose-dependent. Vildagliptin reduces fasting and prandial glucose and HbA1c. It enhances the glucose sensitivity of alpha- and beta-cells and augments glucose-dependent insulin secretion. Fasting and postprandial glucose levels are decreased, and postprandial lipid and lipoprotein metabolism are also improved.

関連反応

1 件
反応記録を作成
HRID 332076 の反応式
HRID 332076反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
InChI
InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12,13,14-,16,17/m0/s1
InChIKey
SYOKIDBDQMKNDQ-XWTIBIIYSA-N
SMILES
N1(C(CNC23CC4CC(CC(O)(C4)C2)C3)=O)CCC[C@H]1C#N
CAS データベース
274901 · 274901-16-5(CAS DataBase Reference)

化学的性質

化学的特性White Solid

Biological Half-LifeThe mean elimination half-life following intravenous administration is approximately two hours. The elimination half-life after oral administration is approximately three hours.
Metabolism/Metabolites · 1 件

About 69% of orally administered vildagpliptin is eliminated via metabolism not mediated by cytochrome P450 enzymes. Based on the findings of a rat study, DPP-4 contributes partially to the hydrolysis of vildagliptin. Vildagliptin is metabolized to pharmacologically inactive cyano (57%) and amide (4%) hydrolysis products in the kidney. LAY 151 (M20.7) is a major inactive metabolite and a carboxylic acid that is formed via hydrolysis of the cyano moiety: it accounts for 57% of the dose. Other circulating metabolites reported are an N-glucuronide (M20.2), an N-amide hydrolysis product (M15.3), two oxidation products, M21.6 and M20.9.

MeSH Pharmacological Classification · 2 件

Substances which lower blood glucose levels.

Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release.

Absorption, Distribution and Excretion · 4 件

In a fasting state, vildagliptin is rapidly absorbed following oral administration. Peak plasma concentrations are observed at 1.7 hours following administration. Plasma concentrations of vildagliptin increase in an approximately dose-proportional manner. Food delays Tmax to 2.5 hours and decreases Cmax by 19%, but has no effects on the overall exposure to the drug (AUC). Absolute bioavailability of vildagliptin is 85%.

Vildagliptin is eliminated via metabolism. Following oral administration, approximately 85% of the radiolabelled vildagliptin dose was excreted in urine and about 15% of the dose was recovered in feces. Of the recovered dose in urine, about 23% accounted for the unchanged parent compound.

The mean volume of distribution of vildagliptin at steady-state after intravenous administration is 71 L, suggesting extravascular distribution.

After intravenous administration to healthy subjects, the total plasma and renal clearance of vildagliptin were 41 and 13 L/h, respectively.

Cellular LocationsExtracellular

用途と製造

UsesUse (kg; approx.) in Germany (2009): >750
応用分野 · 3 件

説明Vildagliptin, a DPP-4 inhibitor, was launched for the oral treatment of type 2 diabetes. Vildagliptin is the second DPP-4 inhibitor to reach the market behind sitagliptin, which was introduced in 2006. DPP-4 inhibitors act by slowing the inactivation of incretins, which are endogenous peptides involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase the synthesis and release of insulin from pancreatic βcells via intracellular signaling pathways involving cAMP. GLP-1 also lowers glucagon secretion from pancreatic α cells, which leads to reduced hepatic glucose production. However, although GLP-1 and GIP effectively lower blood glucose, they are short-lived as a result of rapid inactivation by the ubiquitous serine protease DPP-4. By inhibiting DPP-4, vildagliptin increases the concentration and duration of active incretin levels, which in turn results in increased insulin release and decreased glucagon levels in a glucose-dependent manner. Both vildagliptin and sitagliptin are potent, competitive, reversible inhibitors of DPP- 4 (IC50=3.5 and 18 nM, respectively), and they both show slow, tight-binding inhibition kinetics.

来歴Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.It was approved by the European Medicines Agency (EMA) in 2007. The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/metformin (Eucreas by Novartis) as an oral treatment for type-2 diabetes.

使用Labelled Vildagliptin. It is a new oral anti-hyperglycemic agent of a new dipeptidyl peptidase-IV (DPP-IV) inhibitor class of drugs. Antidiabetic.